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MaCentral sleep apnea (CSA) is a highly prevalent, though often unrecognized, comorbidity in patients with heart failure
(HF). Data from HF population studies suggest that it may present in 30% to 50% of HF patients. CSA is recognized as
an important contributor to the progression of HF and to HF-related morbidity and mortality. Over the past 2 decades,
an expanding body of research has begun to shed light on the pathophysiologic mechanisms of CSA. Armed with this
growing knowledge base, the sleep, respiratory, and cardiovascular research communities have been working to identify
ways to treat CSA in HF with the ultimate goal of improving patient quality of life and clinical outcomes. In this paper,
we examine the current state of knowledge about the mechanisms of CSA in HF and review emerging therapies for
this disorder. (J Am Coll Cardiol 2015;65:72–84) © 2015 by the American College of Cardiology Foundation.C ongestive heart failure (HF) remains a majorpublic health problem and continues to beassociated with substantial morbidity and
mortality. One factor now recognized as contributing
to the excess morbidity and mortality in HF is sleep-
disordered breathing. This condition is characterized
by cycles of signiﬁcant pauses in breathing and par-
tial neurological arousals that ultimately have an
impact on sleep quality and overall health. Sleep-
disordered breathing is broadly classiﬁed into 2 types:
obstructive sleep apnea (OSA) and central sleep apnea
(CSA). The former is common and occurs in both the
general and HF populations, whereas the latter is
more uniquely associated with HF (1–3).
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AB BR E V I A T I O N S
AND ACRONYM S
AHI = apnea-hypopnea index
ASV = adaptive pressure
support servo-ventilation
CPAP = continuous positive
airway pressure
CRT = cardiac
resynchronization therapy
CSA = central sleep apnea
HF = heart failure
LVEF = left ventricular
ejection fraction
NF-kB = nuclear factor-kappa B
OSA = obstructive sleep apnea
ROS = reactive oxygen species
J A C C V O L . 6 5 , N O . 1 , 2 0 1 5 Costanzo et al.
J A N U A R Y 6 / 1 3 , 2 0 1 5 : 7 2 – 8 4 Clinical Consequences of Central Sleep Apnea
73studies suggest that it may reduce OSA-related mor-
tality (10–12).
Most often seen in HF patients, CSA is distinguished
by the temporary withdrawal of central (brainstem-
driven) respiratory drive that results in the cessation
of respiratory muscle activity and airﬂow. In HF pa-
tients, CSA commonly occurs in the form of Cheyne-
Stokes respiration, a form of periodic breathing with
recurring cycles of crescendo-decrescendo ventilation
that culminates in a prolonged apnea or hypopnea.
Like OSA, the presence of CSA in patients with HF is
associated with a set of neurohumoral and hemody-
namic responses that are detrimental to the failing
heart (13–16). However, unlike OSA, the underlying
pathophysiology of CSA and its consequences in HF
have only more recently been recognized and under-
stood. With this expanding knowledge base, clinicians
have been working to identify ways to treat CSA in HF
with the ultimate goal of improving patient quality of
life (QOL) and clinical outcomes. Thus, in this paper,
we will focus on the current state of knowledge about
the mechanisms of CSA in HF and review emerging
therapies for this disorder.
CSA: PRESENTATION AND RISK FACTORS
Highly prevalent in HF, CSA occurs in 30% to 50% of
patients (1–3). Clinically, HF patients with CSA may
experience insomnia, fatigue, and/or daytime sleepi-
ness, although the latter is often absent (17–19). Some-
times, a sleep partner may report witnessed apneas or
the unusual breathing pattern of Cheyne-Stokes
respiration. Patients may also report frequent awak-
enings, poor quality sleep, shortness of breath, parox-
ysmal nocturnal dyspnea, and nocturia (1). However,
because these common ﬁndings can be due to HF itself,
the presence of CSA is often overlooked by patients
and clinicians, and failure to treat CSA potentially leads
to a prognosis worse than that attributable to HF alone.
A number of risk factors have been identiﬁed for the
development of CSA in HF, including male sex, higher
New York Heart Association functional class, lower
ejection fraction, waking hypocapnia (arterial partial
pressure of carbon dioxide [PaCO2] <38 mm Hg),
higher prevalence of atrial ﬁbrillation, higher B-type
natriuretic peptide levels, and frequent nocturnal
ventricular arrhythmias (3,18–20). No questionnaire-
based screening tool has been validated to identify
CSA in HF; therefore, a high index of suspicion for CSA
should exist when 1 or more of these ﬁndings are
present in a patient with HF (21).
DIAGNOSTIC TESTING. The gold standard test for
diagnosing CSA is polysomnography, or overnight
sleep study, which is performed in a sleep laboratory.Characteristic polysomnographic ﬁndings of
CSA include: an onset near the transition into
or out of stage 1, nonrapid eye movement
sleep; cycles of deep, rapid, crescendo-
decrescendo breathing followed by periods
of hypopnea and/or apnea along with con-
comitant changes in blood oxygen saturation;
and apneic periods accompanied by the
absence of chest or abdominal wall activity
(Figure 1) (22). A common measure of the
severity of CSA is the apnea-hypopnea index
(AHI), deﬁned as the mean number of apnea
and/or hypopnea episodes that occur during
sleep divided by the number of hours of
sleep, and is expressed in events per hour.
According to 1 study, receiver-operating ch-
aracteristic analysis of different AHI levels
revealed that an AHI of 22.5 events/h had the greatest
sensitivity and speciﬁcity in predicting mortality
associated with CSA (23). Another study of ambula-
tory HF patients showed that mortality rose progres-
sively with every 5 events/h increase in AHI (24).
Because the detrimental effects of CSA increase with
the increasing number of CSA events, reducing AHI
should be the main focus of treatment.
PATHOGENESIS OF CSA IN HF
The pathogenesis of CSA in HF is complex and re-
mains incompletely understood. However, a sub-
stantial body of research suggests that an increased
respiratory control response to changes in PaCO2
above and below the apneic threshold is central to the
pathogenesis of CSA in HF (25–27). An understanding
of normal respiratory control in both the awake and
sleeping states can aid in understanding the current
theories regarding CSA pathogenesis.
The respiratory control system consists of a com-
plex matrix of peripheral and central receptors and
rhythm generators interacting continuously with the
lung, chest wall, and arterial blood gas content
(28–31). This system operates in a negative feedback
loop while performing its task of maintaining tightly
regulated levels of O2 and CO2 under the numerous
demands from human activity, disease, and aging.
During wakefulness, normal breathing is inﬂuenced
by both metabolic and behavioral factors. Metabolic
factors (such as exercise-induced acidosis or diuretic-
related alkalosis) alter the rate of production of CO2
and modify breathing in response to input from
central and peripheral chemoreceptors. On the basis
of input from these receptors, tidal volume and
breathing rate are modiﬁed to maintain CO2 within a
tight range. Behavioral factors also alter breathing
FIGURE 1 Polysomnogram of CSA in a Patient With Heart Failure
Overnight polysomnography performed in a sleep laboratory remains the gold standard
for diagnosing sleep-disordered breathing. The image highlights characteristic ﬁndings
of central sleep apnea (CSA) on a polysomnogram.
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74through involuntary (e.g., stress) and voluntary (e.g.,
talking or breath holding) respiratory acts.
During sleep, behavioral factors are largely elimi-
nated, leaving the control of breathing entirely to
metabolic factors. Therefore, PaCO2 becomes the only
stimulus for ventilation during sleep. As such, any
increase in PaCO2 will stimulate ventilation, whereas
any decrease in PaCO2 will suppress it. Respiration
will cease altogether if PaCO2 falls below the tightly
regulated level called the apneic threshold. Normally,
at the onset of sleep, ventilation decreases and PaCO2
increases. This keeps the prevailing level of PaCO2
well above the apneic threshold, allowing normal,
rhythmic breathing to continue throughout the night.
In patients with HF, signiﬁcant alterations of sleep
occur at night due to changes associated with their
disease. Three main factors are currently theorized to
interact and lead to respiratory instability in HF: hy-
perventilation, circulatory delay, and cerebrovascular
reactivity. Alterations in these 3 factors destabilize
normal breathing, leading to respiratory instability
and the rhythmic pattern of breathing referred to as
Cheyne-Stokes respiration.
HF patients have a tendency to chronically hyper-
ventilate; why this occurs is not completely under-
stood, although several mechanisms are believed to be
involved (25,26,32). Pulmonary interstitial congestion
due to rostral ﬂuid displacement from the legs to
the chest and lungs while in the supine position
during sleep activates pulmonary stretch receptors
that stimulate ventilation (33–36). Additionally, theunderlying cardiac disease activates peripheral che-
moreceptors, which triggers an exaggerated response
by the body to the lowered level of CO2, resulting in an
apnea. This apnea produces a signiﬁcant increase
in CO2, resulting in another exaggerated response—
hyperventilation—setting up the cyclical pattern
of Cheyne-Stokes respiration (37,38). Upper airway
instability also plays a unique role in CSA. With sleep
onset, upper airway resistance increases due to the
normal sleep-related decrease of muscular tone. It has
been proposed that upper airway obstruction may
promote ventilatory overshoot following the sudden
reduction in upper airway resistance that occurs at
the termination of apnea (39–41). Although any or
all of these factors can lead to the hyperventilation
noted in HF patients with CSA, the resulting
increased ventilatory rate prevents the expected rise
in PaCO2, leading to apnea.
Due to the decreased cardiac output in HF patients,
circulation time increases, which delays detection of
changes in blood gases between the peripheral and
the central chemoreceptors. This prolongs informa-
tion feedback from the peripheral chemoreceptors to
the brain, which ultimately alters respiration. Studies
in HF patients with CSA have shown that lung-to-ear
circulation time, a surrogate measure of circulatory
delay, correlates inversely with cardiac output, and
that circulatory delay inﬂuences the cycle duration of
the waxing-waning pattern of periodic breathing seen
with CSA (42). This was initially believed to be the
primary mechanism of CSA development, but now is
thought to be just 1 of several factors that destabilize
breathing leading to the cyclical breathing pattern
seen in CSA.
Respiratory-induced changes in the PaCO2 play a
key role in regulating cerebral blood ﬂow. Alterations
in cerebral blood ﬂow caused by changes in PaCO2 are
referred to as cerebrovascular reactivity. Studies of
patients with HF and CSA have shown that they have a
diminished cerebrovascular response to CO2 and this
may be another important contributor to the breathing
instabilities seen in these patients during sleep (43).
Because HF patients with CSA have reduced cerebro-
vascular reactivity to CO2, the normal buffering action
to changes in central hydrogen ion concentration
([Hþ]) is impaired, resulting in a greater increase in the
PaCO2 and [Hþ] at the central chemoreceptor during
hypercapnia and a greater reduction in PaCO2 and [Hþ]
during hypocapnia for a given change in PaCO2 (43).
This reduces the ability of the central respiratory con-
trol center to adequately dampen ventilatory un-
dershoots or overshoots, such as those seen during
apnea or at apnea termination. In this way, impaired
cerebrovascular reactivity also may contribute to
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75breathing instabilities during sleep and predispose a
patient to the onset and perpetuation of CSA (43).
Although numerous factors contribute to CSA
development, once begun, the cyclical pattern con-
tinues to perpetuate the instability. Each episode
results in hypoxia and a relative increase in CO2,
which increases the likelihood of the cycle repeating.
Stabilization of gas exchange and/or improvement in
receptor activation is needed to break the abnormal
pattern of breathing.
PATHOPHYSIOLOGIC CONSEQUENCES
Oscillation of the PaCO2 around the apneic threshold
appears to be the key factor in CSA development andCENTRAL ILLUSTRATION Pathophysiologic Consequence
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76SYMPATHETIC NERVOUS SYSTEM ACTIVATION. A
key pathological consequence of CSA in HF is
increased sympathetic nervous system activity
during sleep. Patients with sleep apnea exhibit
repeated bursts of sympathetic activity with each
respiratory event cycle and subsequent arousal
(14,44). In severe cases of CSA, these surges in sym-
pathetic activity may occur many times during the
night and, importantly, arise in addition to the
chronic up-regulation in sympathetic activity already
present in HF (45). This holds high clinical relevance
because increased sympathetic nervous system
activity is associated with increased mortality in
HF patients (46–48). Evidence for further sym-
pathoexcitation during central apneic events comes
from studies demonstrating that overnight urinary
excretion of norepinephrine and early morning
plasma concentrations of norepinephrine are both
elevated in CSA patients (14,49).
The adverse effects of catecholamines in the
setting of HF are well recognized (50). Sustained
sympathetic stimulation causes tachycardia, periph-
eral vasoconstriction, sodium retention, and renin-
angiotensin-aldosterone system (RAAS) activation.
The resulting increases in myocardial oxygen de-
mand, blood pressure, and blood volume lead to
increased myocardial ischemia, pre-load, and after-
load that together further stress the failing heart.
Furthermore, excessive sympathetic activity is asso-
ciated with cardiac myocyte hypertrophy and
apoptosis and focal myocardial necrosis, all of which
contribute to cardiac remodeling. Heightened sym-
pathetic activity also precipitates cardiac arrhythmias
in the setting of left ventricular (LV) dysfunction, and
the additional sympathoexcitation induced by CSA
may further enhance arrhythmogenesis (51). Indeed,
several studies have found that HF patients with CSA
experience increased ventricular irritability including
an increased risk for malignant ventricular arrhyth-
mias (15,51–53) and a frequent association between
atrial ﬁbrillation and CSA (1).
OXIDATIVE STRESS. Oxidative stress is increasingly
recognized as an important pathological mechanism
in the development and progression of HF (54,55). On
the basis of ﬁndings from a number of experimental
and clinical studies, recurrent episodes of intermit-
tent hypoxia-reoxygenation, such as those that occur
with sleep apneas, appear to increase systemic
oxidative stress (56).
Oxidative stress occurs when there is an imbalance
between the production of reactive oxygen species
(ROS) and endogenous antioxidant defenses. ROS,
which are produced via the electron reduction of
molecular oxygen (O2), include superoxide anionradical (O2), hydrogen peroxide (H2O2), and the
hydroxyl radical (OH). Excess ROS cause tissue
damage through oxidative modiﬁcation of essential
cellular biological molecules, such as lipids, proteins,
and deoxyribonucleic acid. ROS are believed to
contribute to HF progression through a number of
different mechanisms, including impairment of
myocardial contractility, involvement in molecular
signaling processes that lead to cardiac remodeling,
and interference with nitric oxide metabolism, which
is critically important to normal endothelial function
(54,55).
With sleep apnea, it has been proposed that excess
ROS are generated by myocytes and other tissues
throughout the body as they attempt to cope with
alternating extremes in oxygen levels experienced
during repeated episodes of hypoxia-reoxygenation
(56). Apnea-induced hypoxia-reoxygenation has
been likened to the events occurring with ischemia-
reperfusion injury seen in the settings of myocardial
infarction, stroke, and other ischemic processes
(57–60). It is postulated that during ischemia-
reperfusion, lack of oxygen leads to the accumula-
tion of metabolic intermediates. With reperfusion,
these reactions proceed with a sudden increase in
ROS, which overwhelms usual cellular antioxidant
defenses, leading to uncontrolled oxidation of vital
cellular biomolecules (56). Experimental data support
this hypothesis, and an expanding body of research
suggests that it may apply to patients with sleep ap-
nea as well (56,61–63).
Clinically, changes in endogenous oxidative stress
are detected by measuring various biomarkers (i.e.,
oxidized products of biological molecules that result
from the production of ROS) in the blood. Widely used
biomarkers of oxidative stress include lipid peroxi-
dation products and oxidized protein and deoxy-
ribonucleic acid (60). In controlled clinical studies of
OSA patients, levels of these biomarkers have been
shown to be elevated, suggesting increased levels of
systemic oxidative stress (60,64–68). Similarly, other
studies have evaluated the antioxidant capacity in
patients with OSA by measuring small molecule
antioxidant levels in the blood. Antioxidant capacity
would be expected to fall in the presence of
increased oxidative stress; thus, its measurement
offers another method of measuring oxidative stress.
Indeed, research has demonstrated decreased anti-
oxidant levels in sleep apnea (60,69,70). Impor-
tantly, oxidative stress has been shown to improve
with the application of CPAP therapy (63,71,72). This
ﬁnding provides important evidence of the potential
role that sleep apnea may have in increasing oxida-
tive stress.
TABLE 1 Central Sleep Apnea and Guidelines
Organization(s),
Year (Ref. #) CSA Treatment Guidelines
American Academy of
Sleep Medicine,
2011 (124)
4.2.1.a CPAP therapy targeted to normalize the AHI is indicated
for the initial treatment of CSAS related to CHF. (STANDARD)
4.2.2.a BPAP therapy in an ST mode targeted to normalize the
AHI may be considered for the treatment of CSAS related to
CHF only if there is no response to adequate trials of CPAP,
ASV, and oxygen therapies. (OPTION)
4.2.3a ASV targeted to normalize the AHI is indicated for the
treatment of CSAS related to CHF. (STANDARD)
4.2.4. Nocturnal oxygen therapy is indicated for the treatment of
CSAS related to CHF. (STANDARD)
4.2.6.a The following therapies have limited supporting evidence
but may be considered for the treatment of CSAS related to
CHF, after optimization of standard medical therapy, if PAP
therapy is not tolerated, and if accompanied by close clinical
follow-up: acetazolamide and theophylline. (OPTION)
American College of
Cardiology/American
Heart Association,
2013 (100)
7.3.1.4. Treatment of Sleep Disorders: Recommendation Class IIa
1. Continuous positive airway pressure can be beneﬁcial to
increase LVEF and improve functional status in patients with
HF and sleep apnea. (Level of Evidence: B)
European Society of
Cardiology, 2012 (145)
11.19 Sleep Disturbance and Sleep-Disordered Breathing
Nocturnal oxygen supplementation, continuous positive
airway pressure, bi-level positive airway pressure, and
adaptive servo-ventilation may be used to treat nocturnal
hypoxemia.
Heart Failure Society of
America, 2010 (146)
6.7 Continuous positive airway pressure to improve daily
functional capacity and quality of life is recommended in
patients with HF and obstructive sleep apnea documented
by approved methods of polysomnography. (Strength of
Evidence ¼ B)
AHI ¼ apnea-hypopnea index; ASV ¼ adaptive servo-ventilation; BPAP ¼ bilevel positive airway pressure; CHF ¼
congestive heart failure; CPAP ¼ continuous positive airway pressure; CSA ¼ central sleep apnea; CSAS ¼ central
sleep apnea syndrome; HF ¼ heart failure; LVEF ¼ left ventricular ejection fraction; PAP ¼ positive airway
pressure; ST ¼ spontaneous timed.
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77INFLAMMATION. Inﬂammation is recognized as
playing a key role in the pathogenesis of cardiovas-
cular disease (CVD), including HF (73–77). In HF,
elevated levels of pro-inﬂammatory mediators are
known to have an adverse impact on LV function
through their effects on cardiac contractility, meta-
bolism, and remodeling (78). Inﬂammation also has
been shown to contribute to pulmonary edema as
well as to the anorexia and cachexia frequently
occurring in patients with advanced HF (75,78).
Elevated levels of pro-inﬂammatory mediators inde-
pendently predict increased mortality in HF patients
(79,80). Similar to oxidative stress, the study of
inﬂammation in sleep apnea has been explored pri-
marily in OSA patients.
Several studies have demonstrated that patients
with sleep apnea have enhanced levels of plasma
markers of systemic inﬂammation. In particular,
increased amounts of pro-inﬂammatory cytokines,
cellular adhesion molecules, and activated circulating
neutrophils have been detected in sleep apnea pa-
tients (81–83). These ﬁndings suggest that sleep ap-
nea, by contributing to the heightened inﬂammatory
state seen in HF patients with sleep apnea, may pro-
mote further HF progression.
Mechanistically, it has been proposed that the
increased levels of ROS resulting from apnea-induced
hypoxia-reoxygenation may trigger the expression of
multiple pro-inﬂammatory genes via activation of
nuclear factor-kappa B (NF-kB) (84–85). NF-kB is
recognized as 1 of the most important oxidation-
sensitive transcription factors, and it plays a key role
in activating numerous genes, including many of
those associated with CVD (86). Studies measuring
NF-kB activity in circulating neutrophils and mono-
cytes in both sleep apnea and control patients have
detected increased NF-kB activity in patients with OSA
(87,88). Importantly, NF-kB activity is reduced by the
application of CPAP therapy, demonstrating a poten-
tial causal link between NF-kB activation and the
pathophysiology of sleep apnea (87,88).
ENDOTHELIAL DYSFUNCTION. Both oxidative stress
and inﬂammation are major components in the initi-
ation and development of endothelial dysfunction, a
critical component of the pathophysiology of many
CVDs including HF (89–91). Endothelial dysfunction
in HF is characterized by a shift of the actions of the
endothelium toward vasoconstriction, inﬂammation,
and thrombosis, which together contribute to the
development of impaired coronary and systemic
perfusion seen in patients with HF (92,93).
Normal endothelial function critically depends
on the presence of nitric oxide. Two major contribu-
tors to endothelial dysfunction include reducedbioavailability of nitric oxide and excess formation of
ROS within the vascular wall (92,94). Reactive oxygen
species are known to reduce bioavailable nitric oxide
and exacerbate local oxidant stress by reacting
directly with nitric oxide to form the potent oxidant,
peroxynitrite (92–95). Apnea-induced intermittent
hypoxia-reoxygenation, through its ability to increase
ROS, may, therefore, contribute to increased endo-
thelial dysfunction. Research has detected the pres-
ence of endothelial dysfunction in patients with OSA
(96). CPAP therapy may reverse this abnormality,
supporting a potential link between sleep apnea and
endothelial dysfunction (96).
TREATMENT
Optimization of HF therapy is of paramount impor-
tance, as a number of studies have shown that once
HF is clinically improved, CSA may improve as well
(97–99). Optimal HF therapy includes diuresis to
reduce pulmonary congestion, beta-blockers to blunt
the effects of sympathetic nervous system activation,
and angiotensin-converting enzyme inhibitors to
reduce ventricular afterload and improve cardiac
output by blockading the effects of the RAAS (100).
FIGURE 2 Practical CSA Management in Patients With Heart Failure
Heart Failure Patient Management
At Each Visit Evaluate for
Sleep Disordered
Breathing (SDB)
SDB
Signs/Sxs?
Risk
Factors?
Overnight Sleep Study
(Polysomnography)
Sleep Study
Demonstrates
CSA?
If OSA, provide
appropriate therapy
If no SDB, reassess
for SDB at Routine
HF Follow-up
NO
YES
YES
NOReassess for SDB at
Routine HF Follow-up
•Optimize Heart Failure Therapy
-Meds (ACE-I, β-blocker, Diuretic Agent, etc)
-Device (Cardiac Resynchronization Therapy)
•Continuous Positive Airway Pressure
•Adaptive Servoventilation
•Transvenous Phrenic Nerve Stimulation
  (investigational)
Current treatment strategies for central sleep apnea (CSA) focus on either improving heart
failure (HF) or reducing CSA itself. ACE-I ¼ angiotensin-converting enzyme inhibitor;
OSA ¼ obstructive sleep apnea; SDB ¼ sleep-disordered breathing; Sxs ¼ symptoms.
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78Additionally, small studies have shown that inotropic
therapy and cardiac transplantation also may reduce
the severity of or resolve CSA in patients with chronic
HF (101–103).
Because CSA often persists despite aggressive
treatment of HF, targeted treatment for CSA must be
considered. It is important to note that, presently,
guidelines offer no consensus regarding the optimal
treatment strategy for CSA in patients with HF
(Table 1). A number of different therapies have been
investigated, and although several have been shown
to be of some beneﬁt in reducing CSA or its symp-
toms, none have proved curative. Also lacking for
most proposed therapies are large-scale, prospective,
randomized trials establishing their safety and efﬁ-
cacy. Thus, current treatment strategies focus on
either improving HF or reducing CSA itself (Figure 2).NONINVASIVE VENTILATORY SUPPORT. Several modes
of noninvasive ventilatory support have been inves-
tigated to treat CSA in HF. The most common and best
studied of these is CPAP therapy. CPAP utilizes a
tight-ﬁtting nasal or facial mask attached to an elec-
tric blower that applies a constant positive pressure
to the airway to maintain patency. It has proven
highly effective in treating OSA, for which it is the
primary therapeutic modality (4,104). In HF patients
with CSA, early, small, short-duration trials of CPAP
showed a number of positive effects, including a
reduction in central apnea/hypopnea events, ven-
tricular ectopic beats, and nocturnal urinary and
daytime plasma norepinephrine levels; an improve-
ment in left ventricular ejection fraction (LVEF) and
QOL; and a trend toward a reduction in mortality and
need for cardiac transplantation (16,52,105,106).
The CANPAP (Canadian Positive Airway Pressure
Trial for Patients with Congestive Heart Failure and
Central Sleep Apnea) was performed to better eval-
uate the potential of CPAP for the treatment of CSA in
HF (107). CANPAP was a large, prospective, multi-
center study that randomized 258 optimally-treated
HF patients with an LVEF <40% and CSA with an
AHI >15 events/h to receive either CPAP or no CPAP.
The primary endpoint of the trial was transplant-free
survival. Secondary endpoints included the effects of
CPAP on LVEF, QOL, exercise tolerance, number of
hospitalizations, and plasma levels of norepinephrine
and atrial natriuretic peptide.
Results from CANPAP were mixed. On average, the
AHI was reduced from 40 to 19 events/h after 3
months of CPAP therapy, and this reduction was
associated with improved nocturnal oxygenation,
exercise tolerance, and LVEF as well as lower plasma
norepinephrine levels. However, CPAP did not
demonstrate any effect on the primary endpoint:
transplant-free survival. Additionally, there was an
early divergence in survival rates that suggested early
worse outcomes in the CPAP-treated group. After a
mean follow-up of 2 years, however, the primary
outcome was identical in the treated and control
groups.
The CANPAP trial experienced a number of limi-
tations that made its results difﬁcult to interpret. Key
among them: poor patient compliance with CPAP
therapy, which, after 1 year, was being used for only
3.6 h/night. Another important issue was that CPAP
therapy did not adequately suppress CSA in 43% of
the study patients. This ﬁnding raised the question of
whether the failure of CPAP to more completely re-
verse CSA during the trial may have been the reason
why the study failed to meet its primary endpoint. To
evaluate this possibility, a post-hoc analysis of the
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were stratiﬁed into 3 groups: control subjects; those
treated with CPAP with suppression of CSA to an
AHI <15 events/h; and those treated with CPAP
without suppression of CSA (AHI >15 events/h). In
the 57% of CANPAP patients who had CPAP reduce
the AHI to <15 events/h, transplant-free survival was
signiﬁcantly increased compared with the control
group (no CPAP), whereas among the 43% of CANPAP
patients where CPAP did not reduce the AHI to <15
events/h, the transplant-free survival did not differ
from that of the control group. These results appeared
to conﬁrm the hypothesis that adequate suppression
of CSA might lead to improved transplant-free
survival.
Overall, CPAP therapy has been shown to afﬂict
unpredictable and, in some cases, adverse effects on
HF patients with CSA. It has been suggested that,
because CPAP increases intrathoracic pressure, it may
cause adverse effects on both right and left ventric-
ular pre-load and afterload that ultimately worsen
rather than improve cardiac function (109). It has also
been proposed that these adverse hemodynamic ef-
fects may have contributed to the early mortality of
the treatment cohort in the CANPAP trial (109).
Because of poor patient compliance and the
variable effects with CPAP therapy, a newer and
potentially better-tolerated and effective type of
noninvasive ventilatory support, called adaptive
pressure support servo-ventilation (ASV), has been
developed and is currently undergoing clinical trials.
ASV was designed to address several aspects of the
respiratory disturbance associated with CSA, in-
cluding ventilatory overshoot and undershoot. Like
CPAP, ASV delivers a baseline continuous positive
airway pressure; however, ASV devices also are
equipped with sensors that can detect central apneas
and deliver several breaths at the tidal volume and
respiratory rate previously determined to match the
patient’s minute ventilation during stable breathing.
The goal of ASV therapy is to prevent the increase in
PaCO2 during apnea and the hyperventilation that
follows, thereby breaking the periodic breathing cycle.
Research suggests that ASV may be better tolerated
than CPAP (110,111), which is likely due to its use of
ventilation algorithms that provide different levels
of pressure support on the basis of the type of sleep-
disordered breathing detected by the device. This
results in greater regulation of the amount of airﬂow
delivered to the patient, making the therapy more
comfortable than CPAP. Nonetheless, the patient still
must wear a mask, which may be difﬁcult for those
who are short of breath or have orthopnea at baseline.
Small studies of ASV have shown it to be moreeffective than CPAP in reducing CSA in HF (110,111).
Additionally, these small studies demonstrated that
ASV improves LVEF, sleep quality, and QOL. Large,
multinational trials are currently underway to see if
ASV will also improve morbidity and mortality in HF
patients with CSA (112,113).
NOCTURNAL OXYGEN SUPPLEMENTATION. Supple-
mental nocturnal oxygen therapy at 2 to 4 l/min by
nasal cannula has been used to treat CSA in pa-
tients with HF. Data from a number of small, short-
term studies have shown that it improves the
AHI (114–122), exercise capacity (117), and LVEF
(114,118,123,124), and reduces serum B-type natri-
uretic peptide levels (119) and sympathetic nervous
system activity (116,123). However, it does not appear
to improve daytime sleepiness or cognitive function
(116) or to have any consistent effect on QOL or sleep
quality (115,116,120).
Research comparing nocturnal oxygen therapy to
CPAP or ASV suggests that it confers no outcomes
advantage over either therapy (108,125,126). Fur-
thermore, unlike CPAP and ASV, nocturnal oxygen
therapy is not effective in eliminating upper airway
obstruction that may accompany central apneas.
Given these ﬁndings, its use is likely best reserved for
those patients whose pressure support therapies are
found to be ineffective or are poorly tolerated.
NOCTURNAL SUPPLEMENTAL CARBON DIOXIDE.
Considering the critical role hypocapnia plays in the
development of CSA in HF, the use of nocturnal
supplemental carbon dioxide administered by nasal
cannula has been investigated as a potential treat-
ment. Small, overnight trials have demonstrated that
inhaled carbon dioxide signiﬁcantly decreases the
AHI, but does not improve sleep quality or reduce the
number of arousals from sleep (127–130).
In addition to a lack of long-term data regarding its
efﬁcacy, supplemental carbon dioxide inhalation is
difﬁcult to safely implement in an unsupervised
outpatient setting. Andreas et al. (130) also provide
evidence that inhaled carbon dioxide may adversely
affect sympathetic nervous system activity, which
would negate any positive effects it might have on
CSA. Thus, supplemental carbon dioxide is not
currently recommended to treat CSA in HF.
CARDIAC PACING. Both cardiac resynchronization
therapy (CRT) and atrial overdrive pacing have been
studied for their effect on CSA in patients with HF. It
is well established that CRT reduces morbidity and
mortality associated with symptomatic HF, and cur-
rent HF treatment guidelines recommend that it be
offered to patients with an LVEF of #35%, a wide QRS
complex ($120 ms), and LV dilation (100). In small
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mented CSA and who received a CRT device, CRT
reduced CSA (131–135) and improved sleep quality
(135). It is presumed that the associated increase in
cardiac output is responsible for its beneﬁcial effects
in HF patients with CSA. However, further long-term,
prospective, randomized trials are needed to conﬁrm
these results. In addition, CRT is restricted in pro-
fessional practice guidelines to only a subset of HF
patients with documented prolongation of the QRS
and LV systolic dysfunction (100). These indications
limit the potential applicability of CRT to treat
CSA in HF patients with a short QRS duration or
preserved LVEF.
Another approach, atrial overdrive pacing, which
paces the heart at a rate higher than the mean
intrinsic atrial rate, has also been investigated in HF
patients with CSA. It has been hypothesized that by
increasing the nocturnal heart rate, atrial overdrive
pacing might increase cardiac output and reduce
pulmonary congestion, therefore reducing or pre-
venting CSA occurrence. In several small studies,
atrial overdrive pacing was shown to reduce the
number of episodes of CSA, improve blood oxygen
saturation, and decrease arousals in patients with HF
(136,137). One study, however, failed to ﬁnd any
improvement in CSA with atrial overdrive pacing
(138). Its effect also appears small when compared to
that of CRT. In a single-blind, randomized, crossover
study evaluating the combined therapeutic impact of
atrial overdrive pacing and CRT on CSA in HF, CRT
alone was shown to signiﬁcantly improve CSA,
whereas CRT plus atrial overdrive pacing produced
only a small, incremental improvement in CSA
(additional reduction in the AHI by 2 events/h) (139).
THEOPHYLLINE AND ACETAZOLAMIDE. Theophyl-
line, a respiratory and cardiac stimulant, has been
suggested for the treatment of CSA in HF. In 1 small,
short-term, double-blind, crossover study in stable
HF patients with CSA, theophylline reduced the
severity of CSA and oxygen desaturation during the
night, but it did not improve LVEF (140). Overall, the
cardiostimulatory and arrhythmogenic effects of
theophylline limit its use in clinical practice until
adequately-powered studies can demonstrate its
long-term safety and efﬁcacy in the HF population.
A mild diuretic agent that causes metabolic
acidosis, acetazolamide also has been proposed to
treat CSA in patients with HF. The metabolic acidosis
induced by acetazolamide has been shown to decrease
PaCO2 and thus increase the amount of PaCO2 needed
to reach the apneic threshold, which may decrease the
likelihood of developing CSA (141,142). In a small,
short, double-blind, prospective trial in HF patientswith CSA, acetazolamide was shown to decrease res-
piratory events, reduce the severity of nocturnal ox-
ygen desaturation, and improve subjective sleep
quality compared with placebo. However, there were
no changes in objective measures of sleep quality and
LVEF (142). Use of acetazolamide in patients with HF is
complicated by the potential for urinary potassium
wasting, leading to hypokalemia and increased risk of
arrhythmia. Thus, use of this agent to treat CSA in HF
awaits larger, longer-term studies of its overall safety
and efﬁcacy.
PHRENIC NERVE STIMULATION. Recently, a new
investigational treatment for CSA has been introduced
utilizing a totally implantable, lead-based system that
provides unilateral transvenous stimulation of the
phrenic nerve to regulate breathing. As a totally
implantable, device-based therapy, it may be better
tolerated than CPAP or ASV in HF patients. Addition-
ally, the device initiates and terminates therapy auto-
matically without patient intervention and thus
should improve patient adherence to treatment.
Early clinical experience with this technology has
been encouraging. In 1 small, multicenter pilot
study (143), HF patients with documented CSA by
polysomnography underwent acute placement of a
neurostimulation lead into either the right brachio-
cephalic vein or the left pericardiophrenic vein. Pa-
tients then underwent polysomnography over 2
nights to compare sleep characteristics during a con-
trol night (no phrenic stimulation) with a therapy
night (phrenic stimulation during episodes of CSA).
Overall, therapy resulted in signiﬁcant improvement
in major indexes of CSA severity, including the AHI,
central apnea index, 4% oxygen desaturation index,
and arousal index. More recently, in a prospective,
international, multicenter, nonrandomized trial in-
volving a broad population of patients with CSA,
unilateral transvenous phrenic nerve stimulation re-
sulted in a 56% decrease in the AHI, and other sleep-
disordered breathing parameters improved as well.
Favorable effects on sleepiness were also noted. The
therapy was found to be well tolerated, and thera-
peutic efﬁcacy was maintained at 6-month follow-up
(144). Active research of phrenic nerve stimulation
for the treatment of CSA is currently ongoing to
further evaluate its safety and efﬁcacy.
CONCLUSIONS
CSA is now recognized as an important, independent
risk factor for worsening HF and reduced survival in
patients with HF. Unfortunately, CSA is often not
identiﬁed by clinicians, because its subtle ﬁndings
often become lost in the signs and symptoms that
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CSA should exist when an HF patient presents with
the clinical features or risk factors of CSA, and in
these patients, an overnight sleep study should be
performed.
Research conducted over the past few decades has
greatly expanded our understanding of causes and
consequences of CSA in HF. Oscillation of the PaCO2
above and below apneic threshold appears to play a
central role in CSA development, although other fac-
tors, including diminished cerebrovascular response
to changes in CO2, upper airway instability, and
increased circulation time (due to decreased cardiac
output), likely also contribute. The adverse conse-
quences of CSA in HF that arise from the repeated
episodes of apnea, hypoxia, reoxygenation, and
arousal throughout the night are multiple and include
sympathetic nervous system activation, oxidative
stress, systemic inﬂammation, and endothelial
dysfunction. All of these pathologic effects are known
to signiﬁcantly contribute to worsening cardiac
function in patients with HF.
Because CSA often manifests due to advanced or
worsening HF, optimizing medical therapy and, when
appropriate, using device-based therapy (e.g., CRT),
are of foremost importance. Research has shown that
once HF is clinically improved, CSA often improves as
well. In cases where CSA persists despite aggressive
treatment of HF, other therapeutic interventions,
such as CPAP or supplemental oxygen therapy,should be considered. Both CPAP and nocturnal ox-
ygen supplementation have been shown to reduce
episodes of CSA, improve cardiac function and exer-
cise capacity, and reduce sympathetic activity. How-
ever, neither therapy has been shown to reduce
mortality, and adherence to CPAP therapy remains a
signiﬁcant problem.
More recently, ASV has been introduced to address
the shortcomings of CPAP therapy, with early expe-
rience suggesting that ASV may be better tolerated
than CPAP and more effective in reducing CSA in HF.
Whether it confers any mortality beneﬁt is still being
investigated. Phrenic nerve stimulation also may
offer a promising new way to treat CSA in HF. Early
data indicate that it signiﬁcantly improves major in-
dexes of CSA severity. Furthermore, as a totally
implantable, device-based therapy, patient adher-
ence is not an issue. Large-scale, long-term, ran-
domized, controlled trials are still needed, however,
to further evaluate its potential clinical impact.
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